PEGylated dual GLP-1/GIP receptor agonist. PEGylation extends the half-life for weekly dosing while dual incretin targeting provides enhanced weight loss and metabolic improvement. Investigational next-generation obesity therapeutic.
Inject SubQ once weekly. Titrate slowly over 8-12 weeks. Monitor for GI side effects during titration. Investigational compound.
Log doses, calculate reconstitution, set reminders, and get AI guidance for Pegapamodutide.
Start Free Trial